Newborn affected by maternal use of antidepressants

nonteratogenic effects of substances transmitted via placenta

• congenital malformations (Q00-Q99)
• encounter for observation of newborn for suspected diseases and conditions ruled out (Z05.-)
• neonatal jaundice from excessive hemolysis due to drugs or toxins transmitted from mother (P58.4)
• newborn in contact with and (suspected) exposures hazardous to health not transmitted via placenta or breast milk (Z77.-)

any current condition in newborn, if applicable

• dysmorphism due to warfarin (Q86.2)
• fetal hydantoin syndrome (Q86.1)

• maternal anesthesia and analgesia in pregnancy, labor and delivery (P04.0)
• maternal use of drugs of addiction (P04.4-)

• , if applicable, withdrawal symptoms from maternal use of drugs of addiction (P96.1)
• withdrawal symptoms from therapeutic use of drugs in newborn (P96.2)

conditions that have their origin in the fetal or perinatal period (before birth through the first 28 days after birth) even if morbidity occurs later

• congenital malformations, deformations and chromosomal abnormalities (Q00-Q99)
• endocrine, nutritional and metabolic diseases (E00-E88)
• injury, poisoning and certain other consequences of external causes (S00-T88)
• neoplasms (C00-D49)
• tetanus neonatorum (A33)

Codes from this chapter are for use on newborn records only, never on maternal records

These codes are for use when the listed maternal conditions are specified as the cause of confirmed morbidity or potential morbidity which have their origin in the perinatal period (before birth through the first 28 days after birth).